CA2832763C - Tetrahydroquinoline derivatives useful as bromodomain inhibitors - Google Patents
Tetrahydroquinoline derivatives useful as bromodomain inhibitors Download PDFInfo
- Publication number
- CA2832763C CA2832763C CA2832763A CA2832763A CA2832763C CA 2832763 C CA2832763 C CA 2832763C CA 2832763 A CA2832763 A CA 2832763A CA 2832763 A CA2832763 A CA 2832763A CA 2832763 C CA2832763 C CA 2832763C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- methyl
- salt
- mmol
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1106743.6 | 2011-04-21 | ||
| GB201106743A GB201106743D0 (en) | 2011-04-21 | 2011-04-21 | Novel compounds |
| PCT/EP2012/057111 WO2012143413A1 (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2832763A1 CA2832763A1 (en) | 2012-10-26 |
| CA2832763C true CA2832763C (en) | 2019-09-24 |
Family
ID=44147335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2832763A Expired - Fee Related CA2832763C (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
Country Status (16)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| ES2704048T3 (es) | 2013-03-14 | 2019-03-14 | Glaxosmithkline Ip No 2 Ltd | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio |
| SG10201707487VA (en) | 2013-03-15 | 2017-10-30 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| JP6461118B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
| NZ714669A (en) | 2013-06-21 | 2021-07-30 | Zenith Epigenetics Ltd | Novel bicyclic bromodomain inhibitors |
| WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EA201690087A1 (ru) | 2013-07-31 | 2016-08-31 | Зенит Эпидженетикс Корп. | Новые квиназолиноны как ингибиторы бромодомена |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| CN106459056A (zh) | 2014-02-10 | 2017-02-22 | 康塞特医药品公司 | 经取代的三唑苯二氮卓 |
| SG11201608843TA (en) | 2014-04-23 | 2016-11-29 | Incyte Corp | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS |
| ES2896400T3 (es) | 2014-08-01 | 2022-02-24 | Nuevolution As | Compuestos activos frente a bromdominios |
| SG11201701043UA (en) | 2014-09-12 | 2017-03-30 | Glaxosmithkline Ip No 2 Ltd | Tetrahydroquinoline derivatives as bromodomain inhibitors |
| WO2016044130A1 (en) | 2014-09-15 | 2016-03-24 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
| RU2697393C2 (ru) * | 2014-10-02 | 2019-08-14 | ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед | Кристаллическая твердая форма соли бензолсульфоновой кислоты и 2-[(4S)-6-(4-хлорфенил)-1-метил-8-(метилокси)-4H-[1,2,4]триазоло[4,3-a][1,4]бензодиазепин-4-ил]-N-этилацетамида, способ ее получения и фармацевтическая композиция, содержащая ее |
| WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
| CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| IL263824B2 (en) | 2016-06-20 | 2023-10-01 | Incyte Corp | Crystals in solid form in the presence of an inhibitor |
| EP3490552B1 (en) | 2016-07-26 | 2022-11-23 | University of Southern California | Selective bromodomain inhibition of fungal bdf1 |
| US11028051B2 (en) * | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| BRPI0416128B8 (pt) | 2003-11-03 | 2021-06-22 | Glaxo Group Ltd | dispositivo de dispensação de fluido |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
| US8791090B2 (en) * | 2009-03-31 | 2014-07-29 | Kowa Company, Ltd. | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient |
| GB0919431D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| EP2955524A3 (en) | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
| GB201106750D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2013033268A2 (en) * | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
-
2011
- 2011-04-21 GB GB201106743A patent/GB201106743D0/en not_active Ceased
-
2012
- 2012-04-19 US US14/111,580 patent/US9029395B2/en not_active Expired - Fee Related
- 2012-04-19 EP EP12716378.0A patent/EP2699550B1/en active Active
- 2012-04-19 SG SG2013076146A patent/SG194469A1/en unknown
- 2012-04-19 BR BR112013026834A patent/BR112013026834A2/pt not_active Application Discontinuation
- 2012-04-19 AU AU2012244759A patent/AU2012244759B2/en not_active Ceased
- 2012-04-19 KR KR1020137030972A patent/KR101896599B1/ko active IP Right Grant
- 2012-04-19 CN CN201280029939.XA patent/CN103619820B/zh not_active Expired - Fee Related
- 2012-04-19 CA CA2832763A patent/CA2832763C/en not_active Expired - Fee Related
- 2012-04-19 ES ES12716378.0T patent/ES2544302T3/es active Active
- 2012-04-19 MX MX2013012190A patent/MX338515B/es active IP Right Grant
- 2012-04-19 WO PCT/EP2012/057111 patent/WO2012143413A1/en active Application Filing
- 2012-04-19 EA EA201391285A patent/EA022341B1/ru not_active IP Right Cessation
- 2012-04-19 JP JP2014505610A patent/JP5840763B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-03 IL IL228707A patent/IL228707A/en active IP Right Grant
- 2013-10-14 ZA ZA2013/07645A patent/ZA201307645B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA022341B1 (ru) | 2015-12-30 |
| KR20140025484A (ko) | 2014-03-04 |
| US20140039006A1 (en) | 2014-02-06 |
| MX338515B (es) | 2016-04-20 |
| GB201106743D0 (en) | 2011-06-01 |
| EP2699550B1 (en) | 2015-06-10 |
| ES2544302T3 (es) | 2015-08-28 |
| SG194469A1 (en) | 2013-12-30 |
| ZA201307645B (en) | 2015-04-29 |
| JP2014511891A (ja) | 2014-05-19 |
| EP2699550A1 (en) | 2014-02-26 |
| IL228707A (en) | 2016-09-29 |
| MX2013012190A (es) | 2014-01-31 |
| EA201391285A1 (ru) | 2014-04-30 |
| CN103619820B (zh) | 2015-08-19 |
| JP5840763B2 (ja) | 2016-01-06 |
| CA2832763A1 (en) | 2012-10-26 |
| BR112013026834A2 (pt) | 2016-12-27 |
| KR101896599B1 (ko) | 2018-09-07 |
| AU2012244759B2 (en) | 2016-03-03 |
| WO2012143413A1 (en) | 2012-10-26 |
| IL228707A0 (en) | 2013-12-31 |
| US9029395B2 (en) | 2015-05-12 |
| CN103619820A (zh) | 2014-03-05 |
| AU2012244759A1 (en) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2832763C (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
| EP3168213B1 (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
| US9861627B2 (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor | |
| EP2705032B1 (en) | Dihydroquinoline derivatives as bromodomain inhibitors | |
| JP5856673B2 (ja) | ７−（３，５−ジメチル−４−イソオキサゾリル）−８−（メチルオキシ）−１Ｈ−イミダゾ［４，５−ｃ］キノリン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170327 |
|
| MKLA | Lapsed |
Effective date: 20210419 |